WechatIMG11.png

  • Home

  • Philosophy

  • People

    • Interns

  • Portfolio Companies

  • News and Events

  • Contact

  • More

    Use tab to navigate through the menu items.
    LATEST NEWS
    Apexigen Publicly Listed Post-Business Combination
    • Aug 1

    Apexigen Publicly Listed Post-Business Combination

    Skyhawk Collaboration with Sanofi
    • Jul 6

    Skyhawk Collaboration with Sanofi

    GrowthCap Top 25 Healthcare Investors - William Dai
    • Apr 28

    GrowthCap Top 25 Healthcare Investors - William Dai

    William Dai named one of GrowthCap's Top 25 Healthcare Investors of 2022
    • Apr 27

    William Dai named one of GrowthCap's Top 25 Healthcare Investors of 2022

    Apexigen to go public via SPAC merger
    • Mar 21

    Apexigen to go public via SPAC merger

    Huma.AI Series A & Product Update
    • Feb 8

    Huma.AI Series A & Product Update

    2022 SVB Report Results
    • Jan 30

    2022 SVB Report Results

    Robert Kamen joins ShangBay Capital as our newest Senior Advisor
    • Nov 2, 2021

    Robert Kamen joins ShangBay Capital as our newest Senior Advisor

    Contraline closes $10.7M Series A Financing Round
    • Oct 20, 2021

    Contraline closes $10.7M Series A Financing Round

    Tvardi Therapeutics among Fierce Biotech's "Fierce 15" of 2021
    • Sep 29, 2021

    Tvardi Therapeutics among Fierce Biotech's "Fierce 15" of 2021

    1
    234

    © 2022 ShangBay Capital. All Rights Reserved